Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
S&K Grey
Boston, MA, USA
- Ownership
- Private
- Development stage
- Other
01
Overview
S&K Grey is a biotechnology company dedicated to developing novel small molecule therapeutics that target the ubiquitin-proteasome system. The company specifically focuses on inhibiting Ubiquitin-specific protease 7 (USP7), an enzyme that regulates the stability of key proteins involved in cancer cell survival and growth. Their lead research programs target pediatric and adult malignancies, including T-cell acute lymphoblastic leukemia and neuroblastoma. Founded by researchers from the Dana-Farber Cancer Institute, S&K Grey leverages deep expertise in chemical biology to create precision medicines for hard-to-treat cancers.
- Therapeutic areas
- Oncology
- Modalities
- Small molecule
- Industry
- Biotech
02
Partnerships
Dana-Farber Cancer Institute
Beyond the preview
Go deeper on S&K Grey.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on S&K Grey.